New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
Recap by typeshit. Post by Facebook on Facebook.
UBS says volumes grew about 55% while net prices fell roughly 14%, and points to about 500,000 people joining Lilly's Medicare bridge program in a few months.
A new market report values the sector at $97.5 billion in 2025 and expects oral and multi-pathway drugs to grow fastest as Medicare coverage starts in mid-2026.
Forbes compares what brand-name semaglutide and tirzepatide cost against compounded GLP-1 versions.
Tirzepatide sales alone beat the total quarterly revenue of Novartis, GSK and BMS. Mounjaro rose 65% and Zepbound 59%.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
A lighthearted Friday post from Saroni about friends refusing to believe her answer on how she lost weight. No details on the drug itself.
Loading…